NDLI: Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.

Please wait, while we are loading the content...

Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients.

Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women.

The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study).

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.

PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: baseline health and healthcare utilization of the US sample.

Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.

Fatty acid synthase inhibitor, C75, blocks resistin-induced increases in lipid accumulation by human macrophages.

Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety.

Year: 2008 Volume: 10 Issue: 11

Year: 2008 Volume: 10 Issue: 10

Year: 2008 Volume: 10 Issue: 9

Year: 2008 Volume: 10 Issue: 8

Year: 2008 Volume: 10 Issue: 7

Year: 2008 Volume: 10 Issue: 6

Year: 2008 Volume: 10 Issue: 5

Year: 2008 Volume: 10 Issue: 4

Year: 2008 Volume: 10 Issue: Supplementary 4

Year: 2008 Volume: 10 Issue: 3

Year: 2008 Volume: 10 Issue: 2

Year: 2008 Volume: 10 Issue: Supplementary 2

Year: 2008 Volume: 10 Issue: Supplementary 1

Year: 2007 Volume: 9

Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Raskin, P.
Description	Country affiliation: United States Author Affiliation: Raskin P ( Department of Internal Medicine, Southwestern Medical Center, Dallas, TX 75390-8858, USA. philip.raskin@utsouthwestern.edu)
Abstract	Type 2 diabetes is characterized by decreases in insulin secretion and insulin sensitivity. Several classes of oral antidiabetic medications are currently approved for the treatment of type 2 diabetes. A stepwise treatment approach from monotherapy to combination therapy is traditionally used; however, the frequency of treatment failure with monotherapy has resulted in a move towards earlier treatment with combination therapies that target the two principal defects in glycaemic control. One such combination regimen is repaglinide (a prandial glucose regulator that increases insulin release) plus metformin (an insulin sensitizer that inhibits hepatic glucose output, increases peripheral glucose uptake and utilization and minimizes weight gain). Findings from several clinical trials have shown that combination therapy with repaglinide plus metformin is well tolerated and results in greater reductions of haemoglobin A(1c) and fasting plasma glucose values compared with either monotherapy. Repaglinide may also provide a more suitable alternative to combination therapy with sulphonylureas and metformin because of its reduced propensity for hypoglycaemia. The combination regimen of repaglinide plus metformin should therefore be considered as a valuable option in the management of patients with type 2 diabetes when monotherapy is no longer adequate.
File Format	HTM / HTML
ISSN	14628902
Issue Number	12
Volume Number	10
e-ISSN	14631326
Journal	Diabetes, Obesity and Metabolism
Language	English
Publisher	Wiley-Blackwell
Publisher Date	2008-12-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Metabolism Discipline Endocrinology Discipline Pharmacology Discipline Diabetology Blood Glucose Metabolism Carbamates Administration & Dosage Diabetes Mellitus, Type 2 Drug Therapy Hypoglycemic Agents Insulin Blood Metformin Piperidines Administration, Oral Drug Therapy, Combination Humans Therapeutic Use Treatment Outcome Weight Gain Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Endocrinology, Diabetes and Metabolism Internal Medicine Endocrinology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.

Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.

Advances in oral therapy for type 2 diabetes.

Diabetes: insulin plus metformin for T2DM--are there benefits?

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial

Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.

Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis.

Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus.

Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.

Similar Documents

Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.

Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.

Advances in oral therapy for type 2 diabetes.

Diabetes: insulin plus metformin for T2DM--are there benefits?

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial

Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.

Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis.

Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus.

Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.